Surgery Partners, Inc. (SGRY) Analyse boursière

Présentation de l'entreprise

Surgery Partners, Inc. owns and operates an extensive network of surgical facilities and ancillary services across the United States, providing ambulatory surgery centers and surgical hospitals for non-emergency procedures in various specialties. The company functions within the Healthcare sector, specifically under the Medical Care Facilities industry, positioning it as a key provider of specialized outpatient surgical care infrastructure. Its scale is substantial, evidenced by a market capitalization of $1.64B, trailing twelve-month revenue of $3.31B, and an employee base of 16,000 individuals. These valuation and revenue figures indicate a significant market footprint, suggesting the company commands a large share of the ambulatory surgical market and operates at a size that supports diverse operational capabilities and ancillary service offerings.

Santé financière

The company reports revenue of $3.31B and EBITDA of $655.50M, while net income stands at $-77,900,000. The substantial gap between the positive EBITDA and the negative net income reveals a cost structure where interest expenses or other non-operating costs are eroding operating profits, resulting in an overall loss for the period. Despite the net loss, the entity generates free cash flow of $164.71M, which provides a critical buffer for financial flexibility, allowing the company to fund capital expenditures or service debt obligations without relying solely on external financing. Profitability analysis shows a gross margin of 23.1%, an operating margin of 15.1%, and a profit margin of -2.4%, indicating that while operational efficiency is maintained in generating revenue, the final bottom line is impacted by high fixed costs or interest burdens. The balance sheet reflects a leveraged position with total debt of $4.04B against cash reserves of $239.90M, resulting in a debt-to-equity ratio of 114.51%. Liquidity is supported by a current ratio of 1.87, which indicates a comfortable ability to meet short-term liabilities with current assets. Return metrics include a return on equity of 2.8% and a return on assets of 3.7%, figures that suggest management effectiveness is currently constrained by the lack of net income, as traditional return measures are suppressed by the reported losses.

Évaluation de la valorisation

Valuation metrics present a mixed picture with a forward P/E of 31.59 and a trailing P/E listed as N/A due to the negative earnings. The absence of a trailing P/E implies that earnings are currently negative, forcing investors to rely on forward-looking estimates that assume a future return to profitability. The price-to-book ratio stands at 0.95, indicating that the market values the company at approximately 95% of its net asset book value, suggesting no significant market premium over the underlying asset value. Alternative valuation metrics such as a price-to-sales ratio of 0.49 and an EV/EBITDA of 11.04 suggest the company is priced conservatively relative to its sales and adjusted earnings power. Price action within the past year shows a 52-week high of $24.18 and a 52-week low of $11.41. Assuming a price near the midpoint of the recent range, the stock trades significantly below its 52-week high of $24.18, reflecting recent market volatility or sentiment shifts. The beta of 1.99 indicates that the stock's price volatility is nearly double that of the broader market, exposing investors to higher risk relative to market movements.

Growth & Income

Revenue growth year-over-year is recorded at 2.4%, while earnings growth is N/A due to the current negative net income. The divergence between steady revenue growth and stagnant earnings growth implies that top-line expansion is not yet translating into bottom-line profitability, likely due to the high leverage or ongoing operational costs. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that the firm retains all earnings rather than distributing them to shareholders. This reinvestment strategy aligns with the need to service debt and fund operations given the current lack of distributable cash from net income. The overall growth and income profile is characterized by stable top-line expansion in a specialized healthcare sector, yet the income profile remains unprofitable with no current dividend support for shareholders.